The aim of this study was to test these biomarkers of NO in glaucoma patients both with and without tinnitus. The objective was also to replicate findings from a previous study performed in Amsterdam, a collaboration between our research group and…
ID
Source
Brief title
Condition
- Glaucoma and ocular hypertension
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Concentrations of amino acids which mark nitric oxide production in glaucoma
patients both with and without tinnitus.
Secondary outcome
N/A
Background summary
Low nitric oxide (NO) bioavailability and oxidative stress may be common
mechanisms behind glaucoma and tinnitus. NO itself diffuses quickly and is
difficult to measure, however, certain metabolites can be measured as
biomarkers of NO production.
Study objective
The aim of this study was to test these biomarkers of NO in glaucoma patients
both with and without tinnitus. The objective was also to replicate findings
from a previous study performed in Amsterdam, a collaboration between our
research group and the AMC
Study design
Observational, cross-sectional
Study burden and risks
Patients who are already scheduled for an appointment in the ophthalmology
clinic and who agree to participate will then be asked to go to the blood draw
clinic after their appointment. Glaucoma patients will not perform any
ophthalmological tests in relation to this study. The blood draw may cause
minimal discomfort or bruising, but is a routine procedure. Patients will
require a maximum of 30 minutes for the blood draw. Healthy controls who send
signed informed consent will be asked to go to the ophthalmology clinic for
screening tests, and then afterwards to get the blood draw. If abnormal eye
screening results are obtained for healthy subjects, they will be referred to
their GP. Detection of signs of glaucoma may cause psychological stress,
however, an early diagnosis will allow treatments to be initiated and therefore
more preservation of visual functioning. Glaucoma patients will not perform any
ophthalmological screening tests; therefore there is no risk of identifying any
other eye conditions. Overall the study causes minimal discomfort and risk to
the patient.
Hanzeplein 1
Groningen 9713 GZ
NL
Hanzeplein 1
Groningen 9713 GZ
NL
Listed location countries
Age
Inclusion criteria
50-70 years of age
For patients only: Diagnosed primary open angle glaucoma
For those with tinnitus, response of tinnitus *always* or *sometimes* in F1
questionnaire
Written informed consent.
Exclusion criteria
Patients taking ototoxic medications will be excluded from this study. These
include: loop diuretics, Apirin, NSAIDs, and chemotherapy agents.
For healthy controls only, glaucoma or family history of glaucoma. This will be
determined by the ophthalmologic screening described in section 3.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL72776.042.20 |